Biogen's license for the sphingosine 1-phosphate (S1P) receptor modulator MT-1303 from Mitsubishi Tanabe Pharma Corp. for up to $544m makes a lot of sense, but with four S1P-targeting drugs approved or in late-stage development did Biogen execute a good deal too late to catch up with the competition?
Cambridge, Massachusetts-based Biogen said on Sept. 9 that it will pay $60m up front and up to $484m in milestone...